medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2005; 52 (1)

Diagnosis of infection for the hepatitis C virus

Vences-Avilés MA, González-Bravo F

Language: Spanish
References: 56
Page: 6-12
PDF size: 57.47 Kb.


ABSTRACT

Objective. The aim of this work was to determine the prevalence of infection for the hepatitis C virus (HCV) in blood donors using a screening test by means of immunoassay (ELISA) and suplementary test recombinant immunoblot (RIBA) and the quantification of the viral RNA by means of Reaction chain Polimerase (PCR). Material and methods. The positive to anti-HCV ELISA blood donors were studied of 1995 at 2003 in the Medical Center of León Guanajuato of Instituto Mexicano del Seguro Social. RIBA and RT-PCR was used to confirm the infection. The risk factors were analyzed in cases confirmed ad not confirmed. Results. Of 49,272 blood donors, 344 were positive (0.70%); 45 of 112 (40%) they were positive and 67 (60%) negative by RIBA test; 41 of 44 RIBA positive were also positive PCR with load viral mean of 5.11 log copias/mL. The associated risk factors to infection were: alcoholism (OR 7.10, IC 95% 1.51-33.4), relate sexual promiscuous (OR 4.01, IC 95% 0.77-20.8), transfusion (OR 62.9, IC 95% 4.19-882) and hospitalizations (OR 1.72 IC 95% 1.72-28.3). Conclusions. The infection prevalence for HCV in blood donors by ELISA test is in agreement with that reported at national level; however, 60% of the positive results for ELISA is false (FP); also, a high agreement exists among a result positive RIBA and detection of viral RNA by means of PCR. On the other hand, risk factors exist “non parenteral” that participate in the epidemiology of the infection in our population and whose final mechanism is necessary to elucidate.


REFERENCES

  1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.

  2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH et al. An assay for circulating antibodies to major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364.

  3. WHO. Hepatitis C: Global update. Wkly Epidemiol Rec 1997; 72: 341-344.

  4. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26: 2-10S.

  5. Alberti A, Chemello L, Benyegnu L. Natural history of hepatitis C. J Hepatol 1999; 31: 17-24.

  6. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5-13.

  7. Dawish MA, Faris R, Clemens JD, Rao MR, Edelman R. High seroprevalence of hepatitis A, B, C and E virus in residents in an Egyptian village in the Nile Delta. Am J Trop Med Hyg 1996; 54: 554-558.

  8. National Blood Service Infection Surveillance. London: PHLS-CDSC, 1998: Report no.8

  9. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. GUT 2001; 5: 707-713.

  10. Vences-Avilés MA. Utilidad de alanina aminotransferasa y anticuerpos contra el virus de hepatitis C en donadores de sangre. Rev Mex Pat Clin 1995; 42: 69-73.

  11. Guerrero-Romero JF, Castañeda A, Rodríguez-Moran M. Prevalence of risk factors associated with hepatitis C in blood donors in the municipaly of Durango, Mexico. Sal Pub Mex 1996; 38: 94-100.

  12. Yee TT, Griftioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985. GUT 2000; 47: 845-851.

  13. Centers for Disease Control and prevention recommendations for prevention and control of hepatitis C Virus (HCV) infection and HCV –related chronic disease. WWWR Morb Mortal Wkly Rep 1998; 47 (RR-19): 1.

  14. Green ST, Mohsen AH, Mckendrick MW. Potential for hepatitis C transmission among non-needle/syringe sharing Sheffield drug injectors through the sharing of drug preparation paraphernalia. Common Dis Public Health 2001; 4: 38-41.

  15. Alvarez Muñoz MT, Vences-Avilés MA, Damacio L, Vázquez-Rosales G, Torres J, González Bravo F et al. Hepatitis C Virus RNA (HCV-RNA) in blood donors and family members seropositive for anti-HCV antibodies. Arch Med Res 2001; 32: 442-445.

  16. Gravousky MO, Minkof HL, Tess BH, Waters DE. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102: 355-359.

  17. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatology 1999; 31 (suppl 1): 80-83.

  18. Lisker M. Asociación Mexicana de Gastroenterología. Consenso de Hepatitis Viral. Grupo Nacional de Consenso de Hepatitis Viral. 1996

  19. Gretch RD. Diagnostic test for hepatitis C. Hepatology 1997; 26 (suppl 1): 43S-47S.

  20. Fleiss LJ. Statistical methods for rates and proportions. 2nd ed. Columbia: John Wiley and Sons, 1981: 19-32

  21. Wayne WD. Bioestadística. Base para el análisis de las ciencias de la salud. México, DF: Limusa, 2002: 519-570.

  22. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993; 2: 155-166.

  23. Williams A, Dodd R. The serology of hepatitis C virus in relation to post-transfusion hepatitis. Ann Clin Lab Sci 1990; 20: 192-199.

  24. Hernández-Pérez RE, Frías–Salcedo JA, Del Ángel-Guevara O. Seroprevalencia de anticuerpos contra el virus de la hepatitis C en donadores de sangre del Hospital Central Militar. Sal Pub Mex 1994; 36: 538-540.

  25. Suoto-Meriño CA, Simón-Domínguez J, Pulido Priego M, Hernández-Pérez A, García-Hernández IC, Del Rio-Chiriboga CA. Prevalencia de marcadores para hepatitis A, B y C en un Hospital de México. Sal Pub Mex 1994; 36: 257-262.

  26. Ayala JJ, Guerra F, Mora P, Casillas A. Prevalencia de marcadores virales para hepatitis B, C y virus de inmunodeficiencia humana en donadores de sangre voluntarios en el noroeste de México. Rev Gastroenterol Mex 1997; 62: 250-253.

  27. Sánchez-Gómez RH, Baptista-González H. Prevalencia de hepatitis B y C en donadores de sangre en un hospital de tercer nivel de la ciudad de México. Sal Pub Mex 1999; 41: 460-465.

  28. Panamerican Health Organization. Blood Bank situation in the region of the Americas, 1996. Epidemiol Bull 1997; 18: 11-12.

  29. World Health Organization. Hepatitis C- global prevalence (update). Wkly Epidemiol Rec 2000; 75: 17-28.

  30. Freíd WH. Diagnostic testing for hepatitis C: Practical considerations. Am J Med 1999; 107 (6B) 31S-35S.

  31. López-Jiménez F, Rohde LEP, Luna-Jiménez MA. Problemas y soluciones en la interpretación de pruebas diagnósticas. Rev Invest Clin 1998; 50: 65-72

  32. Gretch RD, De la Rosa C, Carithers LR, Willson AR, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: Correlation and clinical implications. Ann Intern Med 1995; 123: 321-329.

  33. Dore JG, Kaldor MJ, McCaughan WG. Systematic review of role polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315:333-337.

  34. Hayashi J, Kishihara Y, Yamafi K, Yoshimura E, Kaeakami Y, Akazawa K et al. Transmission of hepatitis C virus by healthy care workers in a rural area of Japan. Am J Gastroenterol 1998; 90: 794-799.

  35. Conry-Cantilena C, Melpolder JC, VanRaden M, Alter HJ. Characteristics and motivation of anti-HCV positive blood donors admitting intravenous drug use. Transfusion 1995; 35: 58S (abstract).

  36. Thomas LD, Astemborski J, Rai MR, Anania AF, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection. Host, viral, and environmental factors. JAMA 2000; 284: 450-456.

  37. Shimoyama R, Sekiguchi S, Suga M, Sakamoto S, Yachi A. The epidemiology and infection route of symptomatic HCV carriers detected through blood donations. Gastroenterol Jpon 1993; 28 (Suppl 5).

  38. Kupek EJ. Residual transfusion risk for hepatitis B and C in southern Brazil. J Viral Hepatol 2001, 8:78-82.

  39. Conry-Cantilena C, VanRaden M, Gibble J, Melpoder J, Shakil AO, Viladomiu L et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996, 334: 1691-1696.

  40. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology 1999, 116: 893-899.

  41. Patiño-Sarcinelli F, Hyman J, Camacho LA, Linhares DB, Azevedo JG. Prevalence and risk factors for hepatitis C antibodies in volunteer blood donors in Brazil. Transfusion 1994, 34: 138-141.

  42. Serfaty L, Giral P, Elghouzzi MH, Jullien AM, Poupon R. Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology 1993; 17: 183-187.

  43. Neal KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent region (UK). Epidemiol Infect 1994; 112: 595-601.

  44. Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors the role of parenteral and sexual transmission. Scand J Infect Dis 1995; 27: 99-104.

  45. Soresi M, Mazzola A, Carroccio A. Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. Hepatogastroenterology 1998, 45: 150-153.

  46. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE. Risk factors for hepatitis C virus infection in United States. Hepatology 2000; 31: 756-762.

  47. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 1995; 74: 212-220.

  48. Waslet A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.

  49. Shev S, Widell A, Bergström T, Hermodsson S, Lindholm A, Norkrans G. Herpes simplex virus-2 may increase susceptibility of the sexual transmission of hepatitis C. Sex Transm Dis 1995; 22: 210-216.

  50. Wejstäl R. Sexual transmission. Proceedings of the International Consensus Conference on Hepatitis C; Feb 26–27; Paris, France. 1999.

  51. Bronowicki JP, Venard V, Botte C, Monhove N, Gastin I, Chone L, et al. Patient to patient transmission of hepatitis C virus infection during colonoscopy. N Engl J Med 1997; 337: 237-240.

  52. Esteban JI, Gómez J, Martell M, Cabot B, Quer J, Campos J. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555-560.

  53. Forns X, Fernández-Llama P, Pons M, Costa J, Ampurdanés S, López-Labrador X. Incidence and risk factors of hepatitis C virus infection in a hemodialysis unit. Nephron Dial Transplant 1997; 12: 736-740.

  54. Mendenhall CL, Moritz T, Rouster S, Roselle G, Polito A, Quan S et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol 1993; 88: 1022-1026.

  55. Schiff RE. Hepatitis C and alcohol. Hepatology 1997; 26 (suppl 1): 39S-42S.

  56. Befrits R, Hedman M, Blomquist L, Allander T, Grillner R, Kinman N et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995; 30: 1113-1118.




2020     |     www.medigraphic.com